84
RIFERIMENTI BIBLIOGRAFICI
1. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., and Thun, M. J. (2008) Cancer Statistics, 2008. CA: A Cancer Journal for Clinicians 58, 71-96
2. Moreno, V., Guino, E., Bosch, F. X., Peinado, M., Capella, G., Navarro, M., Marti, J., Cambray, M., and Lloberas, B. (2002) Diet and K-ras mutations in colorectal cancer. IARC Sci Publ 156, 501-502
3. Lukas, M. (2010) Inflammatory bowel disease as a risk factor for colorectal cancer. Dig Dis 28, 619-624
4. Jass, J. R. (2007) Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50, 113-130
5. Kehoe, J., and Khatri, V. P. (2006) Staging and prognosis of colon cancer. Surg Oncol Clin N Am 15, 129-146
6. Papadopoulos, V. N., Michalopoulos, A., Netta, S., Basdanis, G., Paramythiotis, D., Zatagias, A., Berovalis, P., and Harlaftis, N. (2004) Prognostic significance of mucinous component in colorectal carcinoma. Tech Coloproctol 8 Suppl 1, s123-125
7. Draghicescu, T., Roman, I. C., and Paltanea, L. (1998) Epidemiologic research on the genetic risk factors in gastric and colorectal cancer. Rom J Morphol Embryol 44, 149-152
8. Lynch, H. T., and Lynch, J. (1995) Genetics, natural history, surveillance, management, and gene mapping in the Lynch syndrome. Pathol Biol (Paris) 43, 151-158
9. Kouraklis, G., and Misiakos, E. P. (2005) Hereditary nonpolyposis colorectal cancer (Lynch syndrome): criteria for identification and management. Dig Dis Sci 50, 336-344
85
10. Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjoblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., Silliman, N., Szabo, S., Dezso, Z., Ustyanksky, V., Nikolskaya, T., Nikolsky, Y., Karchin, R., Wilson, P. A., Kaminker, J. S., Zhang, Z., Croshaw, R., Willis, J., Dawson, D., Shipitsin, M., Willson, J. K., Sukumar, S., Polyak, K., Park, B. H., Pethiyagoda, C. L., Pant, P. V., Ballinger, D. G., Sparks, A. B., Hartigan, J., Smith, D. R., Suh, E., Papadopoulos, N., Buckhaults, P., Markowitz, S. D., Parmigiani, G., Kinzler, K. W., Velculescu, V. E., and Vogelstein, B. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113
11. Boyer, J. C., Umar, A., Risinger, J. I., Lipford, J. R., Kane, M., Yin, S., Barrett, J. C., Kolodner, R. D., and Kunkel, T. A. (1995) Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res 55, 6063-6070
12. Rajagopalan, H., Nowak, M. A., Vogelstein, B., and Lengauer, C. (2003) The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer 3, 695-701
13. Fearon, E. R., and Vogelstein, B. (1990) A genetic model for colorectal tumorigenesis. Cell 61, 759-767
14. Laurent-Puig, P., Blons, H., and Cugnenc, P. H. (1999) Sequence of molecular genetic events in colorectal tumorigenesis. Eur J Cancer Prev 8
Suppl 1, S39-47
15. Zhang, B., Ougolkov, A., Yamashita, K., Takahashi, Y., Mai, M., and Minamoto, T. (2003) beta-Catenin and ras oncogenes detect most human colorectal cancer. Clin Cancer Res 9, 3073-3079
16. Reya, T., and Clevers, H. (2005) Wnt signalling in stem cells and cancer. Nature 434, 843-850
17. Morin, P. J., Vogelstein, B., and Kinzler, K. W. (1996) Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci U S A 93, 7950-7954 18. Campbell, S. L., Khosravi-Far, R., Rossman, K. L., Clark, G. J., and Der, C. J. (1998) Increasing complexity of Ras signaling. Oncogene 17, 1395-1413
86
19. Bos, J. L. (1998) All in the family? New insights and questions regarding interconnectivity of Ras, Rap1 and Ral. EMBO J 17, 6776-6782
20. Bos, J. L., Fearon, E. R., Hamilton, S. R., Verlaan-de Vries, M., van Boom, J. H., van der Eb, A. J., and Vogelstein, B. (1987) Prevalence of ras gene mutations in human colorectal cancers. Nature 327, 293-297
21. Boughdady, I. S., Kinsella, A. R., Haboubi, N. Y., and Schofield, P. F. (1992) K-ras gene mutations in adenomas and carcinomas of the colon. Surg Oncol 1, 275-282
22. Edkins, S., O'Meara, S., Parker, A., Stevens, C., Reis, M., Jones, S., Greenman, C., Davies, H., Dalgliesh, G., Forbes, S., Hunter, C., Smith, R., Stephens, P., Goldstraw, P., Nicholson, A., Chan, T. L., Velculescu, V. E., Yuen, S. T., Leung, S. Y., Stratton, M. R., and Futreal, P. A. (2006) Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 5, 928-932
23. Feig, L. A., and Cooper, G. M. (1988) Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins. Mol Cell Biol 8, 2472-2478
24. Gotley, D. C., Reeder, J. A., Fawcett, J., Walsh, M. D., Bates, P., Simmons, D. L., and Antalis, T. M. (1996) The deleted in colon cancer (DCC) gene is consistently expressed in colorectal cancers and metastases. Oncogene 13, 787-795
25. Fearon, E. R., and Pierceall, W. E. (1995) The deleted in colorectal cancer (DCC) gene: a candidate tumour suppressor gene encoding a cell surface protein with similarity to neural cell adhesion molecules. Cancer Surv 24, 3-17
26. Kressner, U., Inganas, M., Byding, S., Blikstad, I., Pahlman, L., Glimelius, B., and Lindmark, G. (1999) Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 17, 593-599
27. Vousden, K. H. (2000) p53: death star. Cell 103, 691-694
28. Basolo, F., Torregrossa, L., Giannini, R., Miccoli, M., Lupi, C., Sensi, E., Berti, P., Elisei, R., Vitti, P., Baggiani, A., and Miccoli, P. (2010) Correlation between the BRAF V600E mutation and tumor invasiveness
87
in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab 95, 4197-4205
29. Caduff, R. F., Svoboda-Newman, S. M., Bartos, R. E., Ferguson, A. W., and Frank, T. S. (1998) Comparative analysis of histologic homologues of endometrial and ovarian carcinoma. Am J Surg Pathol 22, 319-326
30. Brose, M. S., Volpe, P., Feldman, M., Kumar, M., Rishi, I., Gerrero, R., Einhorn, E., Herlyn, M., Minna, J., Nicholson, A., Roth, J. A., Albelda, S. M., Davies, H., Cox, C., Brignell, G., Stephens, P., Futreal, P. A., Wooster, R., Stratton, M. R., and Weber, B. L. (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62, 6997-7000
31. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R., and Futreal, P. A. (2002) Mutations of the BRAF gene in human cancer. Nature 417, 949-954
32. Barault, L., Veyrie, N., Jooste, V., Lecorre, D., Chapusot, C., Ferraz, J. M., Lievre, A., Cortet, M., Bouvier, A. M., Rat, P., Roignot, P., Faivre, J., Laurent-Puig, P., and Piard, F. (2008) Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 122, 2255-2259
33. Brim, H., Mokarram, P., Naghibalhossaini, F., Saberi-Firoozi, M., Al-Mandhari, M., Al-Mawaly, K., Al-Mjeni, R., Al-Sayegh, A., Raeburn, S., Lee, E., Giardiello, F., Smoot, D. T., Vilkin, A., Boland, C. R., Goel, A., Hafezi, M., Nouraie, M., and Ashktorab, H. (2008) Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study. Mol Cancer 7, 68
88
34. Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., and Velculescu, V. E. (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418, 934
35. Finley, G. G., Schulz, N. T., Hill, S. A., Geiser, J. R., Pipas, J. M., and Meisler, A. I. (1989) Expression of the myc gene family in different stages of human colorectal cancer. Oncogene 4, 963-971
36. Salmena, L., Carracedo, A., and Pandolfi, P. P. (2008) Tenets of PTEN tumor suppression. Cell 133, 403-414
37. Orloff, M. S., and Eng, C. (2008) Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. Oncogene 27, 5387-5397
38. Jhawer, M., Goel, S., Wilson, A. J., Montagna, C., Ling, Y. H., Byun, D. S., Nasser, S., Arango, D., Shin, J., Klampfer, L., Augenlicht, L. H., Perez-Soler, R., and Mariadason, J. M. (2008) PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68, 1953-1961 39. Bardelli, A., and Siena, S. (2010) Molecular mechanisms of resistance to
cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28, 1254-1261
40. de Castro-Carpeno, J., Belda-Iniesta, C., Casado Saenz, E., Hernandez Agudo, E., Feliu Batlle, J., and Gonzalez Baron, M. (2008) EGFR and colon cancer: a clinical view. Clin Transl Oncol 10, 6-13
41. Lievre, A., and Laurent-Puig, P. (2008) [Predictive factors of response to anti-EGFR treatments in colorectal cancer]. Bull Cancer 95, 133-140 42. O'Connell, J. B., Maggard, M. A., and Ko, C. Y. (2004) Colon cancer
survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96, 1420-1425
43. van Krieken, J. H., Jung, A., Kirchner, T., Carneiro, F., Seruca, R., Bosman, F. T., Quirke, P., Flejou, J. F., Plato Hansen, T., de Hertogh, G., Jares, P., Langner, C., Hoefler, G., Ligtenberg, M., Tiniakos, D., Tejpar, S., Bevilacqua, G., and Ensari, A. (2008) KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 453, 417-431
89
44. Loong, H. H., Ma, B. B., and Chan, A. T. (2009) Update in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer. J Oncol 2009, 967920
45. Giaccone, G., Iacona, R. B., Fandi, A., Janas, M., Ochs, J. S., Herbst, R. S., and Johnson, D. H. (2009) Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. J Cancer Res Clin Oncol 135, 467-476 46. Wong, S. F. (2005) Cetuximab: an epidermal growth factor receptor
monoclonal antibody for the treatment of colorectal cancer. Clin Ther 27, 684-694
47. Saltz, L. B., Meropol, N. J., Loehrer, P. J., Sr., Needle, M. N., Kopit, J., and Mayer, R. J. (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22, 1201-1208
48. Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., Chau, I., and Van Cutsem, E. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351, 337-345
49. Wu, M., Rivkin, A., and Pham, T. (2008) Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clin Ther 30, 14-30
50. Andreyev, H. J., Norman, A. R., Cunningham, D., Oates, J. R., and Clarke, P. A. (1998) Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 90, 675-684
51. Andreyev, H. J., Norman, A. R., Cunningham, D., Oates, J., Dix, B. R., Iacopetta, B. J., Young, J., Walsh, T., Ward, R., Hawkins, N., Beranek, M., Jandik, P., Benamouzig, R., Jullian, E., Laurent-Puig, P., Olschwang, S., Muller, O., Hoffmann, I., Rabes, H. M., Zietz, C., Troungos, C., Valavanis, C., Yuen, S. T., Ho, J. W., Croke, C. T., O'Donoghue, D. P., Giaretti, W., Rapallo, A., Russo, A., Bazan, V., Tanaka, M., Omura, K., Azuma, T., Ohkusa, T., Fujimori, T., Ono, Y., Pauly, M., Faber, C., Glaesener, R., de Goeij, A. F., Arends, J. W., Andersen, S. N., Lovig, T., Breivik, J.,
90
Gaudernack, G., Clausen, O. P., De Angelis, P. D., Meling, G. I., Rognum, T. O., Smith, R., Goh, H. S., Font, A., Rosell, R., Sun, X. F., Zhang, H., Benhattar, J., Losi, L., Lee, J. Q., Wang, S. T., Clarke, P. A., Bell, S., Quirke, P., Bubb, V. J., Piris, J., Cruickshank, N. R., Morton, D., Fox, J. C., Al-Mulla, F., Lees, N., Hall, C. N., Snary, D., Wilkinson, K., Dillon, D., Costa, J., Pricolo, V. E., Finkelstein, S. D., Thebo, J. S., Senagore, A. J., Halter, S. A., Wadler, S., Malik, S., Krtolica, K., and Urosevic, N. (2001) Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 85, 692-696
52. Lievre, A., Bachet, J. B., Le Corre, D., Boige, V., Landi, B., Emile, J. F., Cote, J. F., Tomasic, G., Penna, C., Ducreux, M., Rougier, P., Penault-Llorca, F., and Laurent-Puig, P. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66, 3992-3995
53. Ciardiello, F., and Tortora, G. (2008) EGFR antagonists in cancer treatment. N Engl J Med 358, 1160-1174
54. Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., and Bardelli, A. (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol
26, 5705-5712
55. Minoo, P., Moyer, M. P., and Jass, J. R. (2007) Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis. J Pathol 212, 124-133 56. Samowitz, W. S., Sweeney, C., Herrick, J., Albertsen, H., Levin, T. R.,
Murtaugh, M. A., Wolff, R. K., and Slattery, M. L. (2005) Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 65, 6063-6069
57. Srinivasan, M., Sedmak, D., and Jewell, S. (2002) Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 161, 1961-1971
58. Gallegos Ruiz, M. I., Floor, K., Rijmen, F., Grunberg, K., Rodriguez, J. A., and Giaccone, G. (2007) EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens. Cell Oncol 29, 257-264
91
59. Nemtsova, M. N., Pal'tseva, E. M., Babaian, A., Mikhailenko, D. S., Babenko, O. V., Samofalova, O., Tsar'kov, P. V., and Zaletaev, D. V. (2008) [Molecular-genetic analysis of clonal intratumoral heterogeneity on colorectal adenocarcinomas]. Mol Biol (Mosk) 42, 1040-1047
60. Mandarano, R., and Ciccone, A. (1995) [Synchronous carcinomas of the colon and rectum]. Minerva Chir 50, 1089-1094
61. Lago, T. F., Pandolfi, U., Castagnoli, L., Malaspina, G. R., Arcidiaco, M., and Uggeri, G. (1988) [Synchronous and metachronous carcinoma of the large intestine]. Chir Ital 40, 93-103
62. Latournerie, M., Jooste, V., Cottet, V., Lepage, C., Faivre, J., and Bouvier, A. M. (2008) Epidemiology and prognosis of synchronous colorectal cancers. Br J Surg 95, 1528-1533
63. Knijn, N., Mekenkamp, L. J. M., Klomp, M., Vink-Börger, M. E., Tol, J., Teerenstra, S., Meijer, J. W. R., Tebar, M., Riemersma, S., van Krieken, J. H. J. M., Punt, C. J. A., and Nagtegaal, I. D. (2011) KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. British Journal of Cancer
104, 1020-1026
64. Losi, L., Benhattar, J., and Costa, J. (1992) Stability of K-ras mutations throughout the natural history of human colorectal cancer. Eur J Cancer
28A, 1115-1120
65. Suchy, B., Zietz, C., and Rabes, H. M. (1992) K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis. Int J Cancer 52, 30-33
66. Zauber, P., Sabbath-Solitare, M., Marotta, S. P., and Bishop, D. T. (2003) Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas. Mol Pathol 56, 137-140
67. Weber, J. C., Meyer, N., Pencreach, E., Schneider, A., Guerin, E., Neuville, A., Stemmer, C., Brigand, C., Bachellier, P., Rohr, S., Kedinger, M., Meyer, C., Guenot, D., Oudet, P., Jaeck, D., and Gaub, M. P. (2007) Allelotyping analyses of synchronous primary and metastasis CIN colon cancers identified different subtypes. Int J Cancer 120, 524-532
92
68. Etienne-Grimaldi, M. C., Formento, J. L., Francoual, M., Francois, E., Formento, P., Renee, N., Laurent-Puig, P., Chazal, M., Benchimol, D., Delpero, J. R., Letoublon, C., Pezet, D., Seitz, J. F., and Milano, G. (2008) K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 14, 4830-4835
69. Oudejans, J. J., Slebos, R. J., Zoetmulder, F. A., Mooi, W. J., and Rodenhuis, S. (1991) Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer
49, 875-879
70. Al-Mulla, F., Going, J. J., Sowden, E. T., Winter, A., Pickford, I. R., and Birnie, G. D. (1998) Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. J Pathol 185, 130-138
71. Albanese, I., Scibetta, A. G., Migliavacca, M., Russo, A., Bazan, V., Tomasino, R. M., Colomba, P., Tagliavia, M., and La Farina, M. (2004) Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun 325, 784-791
72. Oliveira, C., Westra, J. L., Arango, D., Ollikainen, M., Domingo, E., Ferreira, A., Velho, S., Niessen, R., Lagerstedt, K., Alhopuro, P., Laiho, P., Veiga, I., Teixeira, M. R., Ligtenberg, M., Kleibeuker, J. H., Sijmons, R. H., Plukker, J. T., Imai, K., Lage, P., Hamelin, R., Albuquerque, C., Schwartz, S., Jr., Lindblom, A., Peltomaki, P., Yamamoto, H., Aaltonen, L. A., Seruca, R., and Hofstra, R. M. (2004) Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet 13, 2303-2311 73. Artale, S., Sartore-Bianchi, A., Veronese, S. M., Gambi, V., Sarnataro, C.
S., Gambacorta, M., Lauricella, C., and Siena, S. (2008) Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 26, 4217-4219
74. Santini, D., Loupakis, F., Vincenzi, B., Floriani, I., Stasi, I., Canestrari, E., Rulli, E., Maltese, P. E., Andreoni, F., Masi, G., Graziano, F., Baldi, G. G., Salvatore, L., Russo, A., Perrone, G., Tommasino, M. R., Magnani, M., Falcone, A., Tonini, G., and Ruzzo, A. (2008) High concordance of KRAS
